sorafenib has been researched along with amiloride in 5 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (amiloride) | Trials (amiloride) | Recent Studies (post-2010) (amiloride) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 7,584 | 339 | 788 |
Protein | Taxonomy | sorafenib (IC50) | amiloride (IC50) |
---|---|---|---|
Urokinase-type plasminogen activator | Homo sapiens (human) | 4.7 | |
Urokinase-type plasminogen activator | Mus musculus (house mouse) | 2.3 | |
Amine oxidase [flavin-containing] A | Homo sapiens (human) | 3.909 | |
Sodium/hydrogen exchanger 1 | Rattus norvegicus (Norway rat) | 1 | |
Amiloride-sensitive sodium channel subunit alpha | Homo sapiens (human) | 0.776 | |
Sodium/hydrogen exchanger 2 | Oryctolagus cuniculus (rabbit) | 1 | |
Acid-sensing ion channel 3 | Homo sapiens (human) | 4.4 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Mihaila, RG | 1 |
Chang, CS; Chang, JG; Chang, WH; Chang, YS; Chen, YC; Chen, YT; Hsu, KC; Lee, CC; Lin, SY; Liu, TY; Wu, YC; Yang, JM | 1 |
Kinoshita, Y; Matsuda, Y; Osawa, M; Wakai, T | 1 |
2 review(s) available for sorafenib and amiloride
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology.
Topics: Amiloride; Antineoplastic Agents; Apoptosis; Cation Transport Proteins; Cell Line, Tumor; DNA Damage; Drug Interactions; fms-Like Tyrosine Kinase 3; Genes, abl; Guanidines; Heme Oxygenase-1; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Osmolar Concentration; Patents as Topic; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Sulfones; Tumor Hypoxia; Up-Regulation | 2015 |
3 other study(ies) available for sorafenib and amiloride
Article | Year |
---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Alternative splicing in human cancer cells is modulated by the amiloride derivative 3,5-diamino-6-chloro-N-(N-(2,6-dichlorobenzoyl)carbamimidoyl)pyrazine-2-carboxide.
Topics: Alternative Splicing; Amiloride; Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; G2 Phase; Gene Expression Regulation, Neoplastic; Genome, Human; Heterogeneous-Nuclear Ribonucleoproteins; Histones; Humans; Mice, Inbred BALB C; Mitosis; Models, Molecular; Molecular Targeted Therapy; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Pyrimidines; RNA, Messenger; Serine-Arginine Splicing Factors; Sorafenib; Xenograft Model Antitumor Assays | 2019 |
Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells.
Topics: Amiloride; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Male; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Sorafenib; Xenograft Model Antitumor Assays | 2021 |